| 001 | 180921 | ||
| 005 | 20240229145635.0 | ||
| 024 | 7 | _ | |a 10.1186/s13063-022-06556-7 |2 doi |
| 024 | 7 | _ | |a pmid:35906659 |2 pmid |
| 024 | 7 | _ | |a 1468-6694 |2 ISSN |
| 024 | 7 | _ | |a 1468-6708 |2 ISSN |
| 024 | 7 | _ | |a 1745-6215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:133373303 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01646 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hiensch, Anouk E |0 0000-0002-6216-2609 |b 0 |
| 245 | _ | _ | |a Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study. |
| 260 | _ | _ | |a London |c 2022 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1662470881_21383 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C110#LA:C110# / 2022 Jul 29;23(1):610 |
| 520 | _ | _ | |a Many patients with metastatic breast cancer experience cancer- and treatment-related side effects that impair activities of daily living and negatively affect the quality of life. There is a need for interventions that improve quality of life by alleviating fatigue and other side effects during palliative cancer treatment. Beneficial effects of exercise have been observed in the curative setting, but, to date, comparable evidence in patients with metastatic breast cancer is lacking. The aim of this study is to assess the effects of a structured and individualized 9-month exercise intervention in patients with metastatic breast cancer on quality of life, fatigue, and other cancer- and treatment-related side effects.The EFFECT study is a multinational, randomized controlled trial including 350 patients with metastatic breast cancer. Participants are randomly allocated (1:1) to an exercise or control group. The exercise group participates in a 9-month multimodal exercise program, starting with a 6-month period where participants exercise twice a week under the supervision of an exercise professional. After completing this 6-month period, one supervised session is replaced by one unsupervised session for 3 months. In addition, participants are instructed to be physically active for ≥30 min/day on all remaining days of the week, while being supported by an activity tracker and exercise app. Participants allocated to the control group receive standard medical care, general written physical activity advice, and an activity tracker, but no structured exercise program. The primary outcomes are quality of life (EORTC QLQ-C30, summary score) and fatigue (EORTC QLQ-FA12), assessed at baseline, 3, 6 (primary endpoint), and 9 months post-baseline. Secondary outcomes include physical fitness, physical performance, physical activity, anxiety, depression, pain, sleep problems, anthropometric data, body composition, and blood markers. Exploratory outcomes include quality of working life, muscle thickness, urinary incontinence, disease progression, and survival. Additionally, the cost-effectiveness of the exercise program is assessed. Adherence and safety are monitored throughout the intervention period.This large randomized controlled trial will provide evidence regarding the (cost-) effectiveness of exercise during treatment of metastatic breast cancer. If proven (cost-)effective, exercise should be offered to patients with metastatic breast cancer as part of standard care.ClinicalTrials.gov NCT04120298 . Registered on October 9, 2019. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Exercise |2 Other |
| 650 | _ | 7 | |a Fatigue |2 Other |
| 650 | _ | 7 | |a Metastatic breast cancer |2 Other |
| 650 | _ | 7 | |a Quality of life |2 Other |
| 650 | _ | 7 | |a Randomized controlled trial |2 Other |
| 700 | 1 | _ | |a Monninkhof, Evelyn M |b 1 |
| 700 | 1 | _ | |a Schmidt, Martina |0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac |b 2 |e First author |u dkfz |
| 700 | 1 | _ | |a Zopf, Eva M |b 3 |
| 700 | 1 | _ | |a Bolam, Kate A |b 4 |
| 700 | 1 | _ | |a Aaronson, Neil K |b 5 |
| 700 | 1 | _ | |a Belloso, Jon |b 6 |
| 700 | 1 | _ | |a Bloch, Wilhelm |b 7 |
| 700 | 1 | _ | |a Clauss, Dorothea |0 P:(DE-He78)f52b77d7ab843c9b900134aafc61638a |b 8 |u dkfz |
| 700 | 1 | _ | |a Depenbusch, Johanna |0 P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5 |b 9 |u dkfz |
| 700 | 1 | _ | |a Lachowicz, Milena |b 10 |
| 700 | 1 | _ | |a Pelaez, Mireia |b 11 |
| 700 | 1 | _ | |a Rundqvist, Helene |b 12 |
| 700 | 1 | _ | |a Senkus, Elzbieta |b 13 |
| 700 | 1 | _ | |a Stuiver, Martijn M |b 14 |
| 700 | 1 | _ | |a Trevaskis, Mark |b 15 |
| 700 | 1 | _ | |a Urruticoechea, Ander |b 16 |
| 700 | 1 | _ | |a Rosenberger, Friederike |b 17 |
| 700 | 1 | _ | |a van der Wall, Elsken |b 18 |
| 700 | 1 | _ | |a de Wit, G Ardine |b 19 |
| 700 | 1 | _ | |a Zimmer, Philipp |b 20 |
| 700 | 1 | _ | |a Wengström, Yvonne |b 21 |
| 700 | 1 | _ | |a Steindorf, Karen |0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756 |b 22 |e Last author |u dkfz |
| 700 | 1 | _ | |a May, Anne M |b 23 |
| 773 | _ | _ | |a 10.1186/s13063-022-06556-7 |g Vol. 23, no. 1, p. 610 |0 PERI:(DE-600)2040523-6 |n 1 |p 610 |t Trials |v 23 |y 2022 |x 1468-6694 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:180921 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)f52b77d7ab843c9b900134aafc61638a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2018-09-24T10:24:34Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2018-09-24T10:24:34Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Open peer review |d 2018-09-24T10:24:34Z |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TRIALS : 2021 |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-25 |
| 920 | 2 | _ | |0 I:(DE-He78)C110-20160331 |k C110 |l Bewegung, Präventionsforschung und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C110-20160331 |k C110 |l Bewegung, Präventionsforschung und Krebs |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)C110-20160331 |k C110 |l Bewegung, Präventionsforschung und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C110-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::